2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
26
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
HER2-positive Breast Cancer
3
Advanced Solid Tumor
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Interventions
Paclitaxel
13
pembrolizumab
8
Carboplatin
7
Surveys and Questionnaires
6
Cisplatin
6
Brachytherapy
5
Doxorubicin
4
Docetaxel
4
Pemetrexed
3
Hyperthermic Intraperitoneal Chemotherapy
3
Gemcitabine
3
FANG vaccine
3
Biopsy
3
osimertinib
2
olaparib
2
niraparib
2
durvalumab
2
adavosertib
2
Trastuzumab
2
Topotecan
2
Taxes
2
Standard of Care
2
Sentinel Lymph Node Biopsy
2
Saline Solution
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Nivolumab
2
Music Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled